Skip to main content

Table 3 Unadjusted and adjusted Cox models for breast cancer specific mortality stratified by molecular subtype showing the effect of each age group (compared to the reference group of women aged 50 to 69 years) in each molecular subtype

From: Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland

Subtype

 

Unadjusted

HR (95% CI)

P value

Adjusted

HR (95% CI)

P value

 

Deaths/cases*

< 50 years

70 years or older

< 50 years

70 years or older

ER+

5,238/42,146

1.43 (1.33–1.53)

2.35 (2.21–2.50)

0.89 (0.82–0.96)

1.34 (1.24–1.45)

ER-

2,378/9,105

1.07 (0.96–1.18)

2.09 (1.90–2.29)

0.92 (0.83–1.02)

1.30 (1.16–1.46)

Luminal A

723/13,755

1.42 (1.11–1.81)

4.60 (3.91–5.42)

0.66 (0.51–0.86)

1.49 (1.23–1.80)

Luminal B

753/7,132

1.21 (1.01–1.46)

2.62 (2.22–3.09)

1.10 (0.90–1.34)

1.39 (1.14–1.69)

HER2-expressed

147/1,034

0.88 (0.55–1.42)

2.86 (2.01–4.09)

0.64 (0.39–1.06)

0.72 (0.45–1.16)

TNBC

453/2,519

1.24 (0.98–1.56)

2.32 (1.87–2.88)

1.07 (0.84–1.37)

1.49 (1.15–1.94)

  1. Footnote: *Number of deaths/cases restricted to the complete case analysis models (patients with all variables in the adjusted model). Adjusted model includes age at diagnosis, incidence year, NHS region, grade (only in the HER2-enriched and TNBC models), TNM stage, method of detection, surgery, radiotherapy, chemotherapy, hormone therapy (only for luminal models), SIMD and Charlson score index. HRs reported are for the comparison of each specific age group with the reference age group of 50 to 69 years. HRs in bold were statistically significant at the 0.1% level (p < 0.001). CI = confidence interval, ER=oestrogen receptor, HER2= human epidermal growth factor 2, HR = hazard ratio, NHS = National Health Service, SIMD = Scottish Index of Multiple Deprivation, TNBC = triple negative breast cancer, TNM = tumour, nodes,metastases